CN114736209B - Zinc-europium-porphyrin phosphorus cluster material and preparation method and application thereof - Google Patents
Zinc-europium-porphyrin phosphorus cluster material and preparation method and application thereof Download PDFInfo
- Publication number
- CN114736209B CN114736209B CN202210288425.1A CN202210288425A CN114736209B CN 114736209 B CN114736209 B CN 114736209B CN 202210288425 A CN202210288425 A CN 202210288425A CN 114736209 B CN114736209 B CN 114736209B
- Authority
- CN
- China
- Prior art keywords
- europium
- porphyrin
- black phosphorus
- zinc
- phosphorus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Zinc-europium-porphyrin phosphorus Chemical compound 0.000 title claims abstract description 69
- 239000000463 material Substances 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title abstract description 20
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 97
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 52
- 229910052693 Europium Inorganic materials 0.000 claims abstract description 42
- NNMXSTWQJRPBJZ-UHFFFAOYSA-K europium(iii) chloride Chemical compound Cl[Eu](Cl)Cl NNMXSTWQJRPBJZ-UHFFFAOYSA-K 0.000 claims abstract description 18
- HHDUMDVQUCBCEY-UHFFFAOYSA-N 4-[10,15,20-tris(4-carboxyphenyl)-21,23-dihydroporphyrin-5-yl]benzoic acid Chemical compound OC(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)C(O)=O)c2ccc([nH]2)c(-c2ccc(cc2)C(O)=O)c2ccc(n2)c(-c2ccc(cc2)C(O)=O)c2ccc1[nH]2 HHDUMDVQUCBCEY-UHFFFAOYSA-N 0.000 claims abstract description 14
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims abstract description 14
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004246 zinc acetate Substances 0.000 claims abstract description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 142
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 48
- 239000011701 zinc Substances 0.000 claims description 48
- 238000006243 chemical reaction Methods 0.000 claims description 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 238000005406 washing Methods 0.000 claims description 19
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 11
- 229910052698 phosphorus Inorganic materials 0.000 claims description 11
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 230000035484 reaction time Effects 0.000 claims description 9
- 229910052725 zinc Inorganic materials 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 238000001237 Raman spectrum Methods 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000000026 X-ray photoelectron spectrum Methods 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 238000010531 catalytic reduction reaction Methods 0.000 claims description 3
- DQGZFESXKKEXEF-UHFFFAOYSA-N C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.C(=O)(O)C2=CC=C(C=C2)[Zn](C2=CC=C(C=C2)C(=O)O)(C2=CC=C(C=C2)C(=O)O)C2=CC=C(C=C2)C(=O)O Chemical compound C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.C(=O)(O)C2=CC=C(C=C2)[Zn](C2=CC=C(C=C2)C(=O)O)(C2=CC=C(C=C2)C(=O)O)C2=CC=C(C=C2)C(=O)O DQGZFESXKKEXEF-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 12
- 241000894006 Bacteria Species 0.000 abstract description 6
- 238000006555 catalytic reaction Methods 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004729 solvothermal method Methods 0.000 abstract 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 39
- 229950006238 nadide Drugs 0.000 description 39
- 239000000243 solution Substances 0.000 description 37
- 150000004032 porphyrins Chemical class 0.000 description 24
- 238000010521 absorption reaction Methods 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 238000006722 reduction reaction Methods 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- JIRMQEPRKFTWOK-UHFFFAOYSA-L O.O.O.O.O.O.[Zn+2].CC([O-])=O.CC([O-])=O Chemical compound O.O.O.O.O.O.[Zn+2].CC([O-])=O.CC([O-])=O JIRMQEPRKFTWOK-UHFFFAOYSA-L 0.000 description 5
- 241000316887 Saissetia oleae Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- LEHSVHAPUYAXGP-UHFFFAOYSA-N C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.[Eu] Chemical compound C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.[Eu] LEHSVHAPUYAXGP-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004635 cellular health Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001453 impedance spectrum Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229910052976 metal sulfide Inorganic materials 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/14—Phosphorus; Compounds thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
- B01J31/1805—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
- B01J31/181—Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
- B01J31/1825—Ligands comprising condensed ring systems, e.g. acridine, carbazole
- B01J31/183—Ligands comprising condensed ring systems, e.g. acridine, carbazole with more than one complexing nitrogen atom, e.g. phenanthroline
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
- B01J31/2208—Oxygen, e.g. acetylacetonates
- B01J31/2226—Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
- B01J31/223—At least two oxygen atoms present in one at least bidentate or bridging ligand
- B01J31/2239—Bridging ligands, e.g. OAc in Cr2(OAc)4, Pt4(OAc)8 or dicarboxylate ligands
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
- B01J31/2208—Oxygen, e.g. acetylacetonates
- B01J31/2226—Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
- B01J31/2243—At least one oxygen and one nitrogen atom present as complexing atoms in an at least bidentate or bridging ligand
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
- B01J35/39—Photocatalytic properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/34—Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves ; Ionic sputtering; Flame or plasma spraying; Particle radiation
- B01J37/341—Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves ; Ionic sputtering; Flame or plasma spraying; Particle radiation making use of electric or magnetic fields, wave energy or particle radiation
- B01J37/343—Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves ; Ionic sputtering; Flame or plasma spraying; Particle radiation making use of electric or magnetic fields, wave energy or particle radiation of ultrasonic wave energy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
- C07F19/005—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/06—Zinc compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6596—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having atoms other than oxygen, sulfur, selenium, tellurium, nitrogen or phosphorus as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/60—Reduction reactions, e.g. hydrogenation
- B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
- B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/60—Reduction reactions, e.g. hydrogenation
- B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
- B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
- B01J2231/646—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of aromatic or heteroaromatic rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
- B01J2531/0213—Complexes without C-metal linkages
- B01J2531/0216—Bi- or polynuclear complexes, i.e. comprising two or more metal coordination centres, without metal-metal bonds, e.g. Cp(Lx)Zr-imidazole-Zr(Lx)Cp
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
- B01J2531/0238—Complexes comprising multidentate ligands, i.e. more than 2 ionic or coordinative bonds from the central metal to the ligand, the latter having at least two donor atoms, e.g. N, O, S, P
- B01J2531/0241—Rigid ligands, e.g. extended sp2-carbon frameworks or geminal di- or trisubstitution
- B01J2531/025—Ligands with a porphyrin ring system or analogues thereof, e.g. phthalocyanines, corroles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/20—Complexes comprising metals of Group II (IIA or IIB) as the central metal
- B01J2531/26—Zinc
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/30—Complexes comprising metals of Group III (IIIA or IIIB) as the central metal
- B01J2531/38—Lanthanides other than lanthanum
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/06—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing polymers
- B01J31/069—Hybrid organic-inorganic polymers, e.g. silica derivatized with organic groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Plasma & Fusion (AREA)
- Toxicology (AREA)
- Catalysts (AREA)
Abstract
The invention provides a zinc-europium porphyrin phosphorus cluster material and a preparation method and application thereof, wherein lamellar black phosphorus and europium chloride react with black phosphorus under the noise condition to form europium-doped black phosphorus containing P-Eu and O-Eu bonds; then, reacting tetra (4-carboxyphenyl) porphyrin, zinc acetate and europium-doped black phosphorus by utilizing a solvothermal reaction to obtain a zinc-europium-porphyrin phosphorus cluster material; the material prepared by the invention has better photo-thermal property, and can convert NAD into NAD under the drive of visible light + Reduction to NADH, useful in vivo NAD + The reduction and catalysis of the material are expected to become a novel green bacteria inhibiting material.
Description
Technical Field
The invention relates to a zinc-europium porphyrin phosphorus cluster material and a preparation method and application thereof, belonging to the technical field of material preparation and application.
Background
NAD in Normal organisms + the/NADH ratio is always in a state of dynamic equilibrium, and this ratio is a very important index that reflects the redox state of a cell, thereby determining the metabolic activity of a cell and the health of a cell. Nicotinamide Adenine Dinucleotide (NAD) + ) And the reduced NADH thereof are important coenzymes in the life process, and participate in the redox metabolism and other a series of important biochemical processes in the life body. Human body to NAD + And NADH requirements affect the ratio between the two, thereby having various effects on cellular health and biological processes. The research finds that the intervention of mitochondria targeting NADH (reduced state of nicotinamide adenine dinucleotide)/NAD + (Nicotinamide adenine dinucleotide, abbreviated as NAD) + ) The ratio, increasing the amount of NADH, can block the electron transmission of bacteria, thus interfering the expression of cell energy and related genes and reducing the bacterial infection rate.
The treatment of bacterial infection is mainly antibiotics, and the abuse of antibiotics causes the bacteria to generate drug resistance, thereby greatly reducing the curative effect of the antibiotics. The development of low-toxicity high-efficiency green nano antibacterial materials becomes a hot trend of research in recent years, the effect of a nano and biological interface can effectively treat bacterial infection, and the preparation of novel photothermal antibacterial materials by utilizing near infrared light with low phototoxicity on the basis of selecting low-toxicity materials is the current development direction.
Black scale (BP) toolThe metal-modified BP has good biocompatibility, near infrared absorption and good photo-thermal performance, in recent years, the metal-modified BP generates Reactive Oxygen Species (ROS) under the action of near infrared light, and the ROS kills tumors and bacteria, so that the metal-modified BP is a good photodynamic therapeutic agent. However, the black phosphorus has poor stability in air, and the black phosphorus itself can be rapidly degraded when exposed to air and water, thereby seriously affecting the application capability. However, other conventional photothermal antibacterial materials mainly comprise metal sulfides and metal oxides, but these photothermal preparations are degraded slowly, and are easy to cause biological safety problems such as physiological rejection. Thus, the study of NAD + The reduction reagent is expected to be used for regulating cell reduction in the field of biomedicine and becomes a novel compound for resisting infection and activating immunity.
Disclosure of Invention
Aiming at some defects in the prior art, the invention provides a zinc-europium porphyrin phosphorus cluster material (marked as BP @ Eu-TCPP-Zn) and a preparation method and application thereof.
The invention firstly provides a zinc-europium-porphyrin phosphorus cluster material, which is marked as BP @ Eu-TCPP-Zn, the zinc-europium-porphyrin phosphorus cluster material is composed of a lamellar structure with the average width of 1 mu m, the mass percentage content of metal europium and zinc in the zinc-europium-porphyrin phosphorus cluster material is respectively 1.5% and 6.8%, and the zinc-europium-porphyrin phosphorus cluster material contains europium black phosphorus and tetra (4-carboxyphenyl) zinc porphyrin.
The infrared spectrogram is 1650cm -1 Is the stretching vibration peak of C = O in tetracarboxyl porphyrin, and is 1600-1400cm -1 A plurality of absorption peaks at (a) are attributed to the characteristic absorption of the porphyrin; raman spectrum at 683cm -1 And 737cm -1 The absorption peaks of (a) are formed P-Eu bond and O-Eu bond. 2430cm -1 The absorption peak is from the absorption of porphyrin; raman and XPS spectra show P-Eu and P-P bonds.
XPS spectrogram shows that the compound mainly comprises C, N, P, O, zn and Eu elements; wherein trivalent europium is bound to phosphorus in a coordinated fashion and divalent zinc is coordinated to the porphyrin.
The invention also provides a preparation method of the zinc-europium-porphyrin-phosphorus cluster material BP @ Eu-TCPP-Zn, in the invention, lamellar black phosphorus is obtained by a liquid-phase ultrasonic stripping method, and rare earth europium is loaded on the surface of the lamellar black phosphorus by utilizing P-Eu and O-Eu bonds formed by the black phosphorus, surface phosphate radicals and europium ions; then tetra (4-carboxyphenyl) porphyrin and europium are further coordinated, porphyrin is bridged on the surface of black phosphorus, and the absorption capacity and the electron transfer capacity of the black phosphorus to light are improved under the action of a porphyrin photosensitizer; the pyrrole ring at the center of the porphyrin can be combined with transition metal, and the combination of the porphyrin and the metal can obviously improve the photoelectric effect, so that zinc ions which have an inhibiting effect on bacteria are introduced into the center of the porphyrin to obtain the novel zinc-europium porphyrin phosphorus cluster material.
The preparation method of the zinc-europium-porphyrin phosphorus cluster material comprises the following steps:
(1) Adding blocky black phosphorus and N-octylamine into an N-methylpyrrolidinone (NMP) solution, and carrying out ultrasonic stripping in ice bath to obtain the lamellar black phosphorus.
Wherein the dosage proportion of the blocky black phosphorus, the NMP and the n-octylamine is as follows: 100mg:40-120mL:0.1-20mL; preferably, the dosage ratio of the blocky black phosphorus, the NMP and the n-octylamine is as follows: 100mg:90mL:10mL;
the ultrasonic power is 800w, and the ultrasonic time is 5-60 hours, preferably 30 hours.
(2) Respectively dispersing the lamellar black phosphorus and europium trichloride in a DMF (dimethyl formamide) solution, slowly dropwise adding the DMF solution of europium trichloride into the DMF solution of lamellar black phosphorus, uniformly mixing, transferring the mixture into a reaction kettle for reaction, centrifuging after the reaction is finished, washing with DMF and acetonitrile, and drying in vacuum to obtain the europium black phosphorus compound.
Wherein, the molar ratio of the lamellar black phosphorus to the europium trichloride is 1-20;
the reaction temperature is 80-200 ℃, and the reaction time is 5-60 hours; preferably, the reaction temperature is 140 ℃ and the reaction time is 24 hours.
(3) Respectively dispersing the europium black phosphorus compound and tetra (4-carboxyphenyl) porphyrin in a DMF solution, uniformly mixing the two solutions, transferring the mixture into a reaction kettle for reaction, centrifuging after the reaction is finished, washing with DMF and acetonitrile, and drying in vacuum to obtain the europium black phosphorus porphyrin.
Wherein the mass ratio of the europium black phosphorus compound to the tetra (4-carboxyphenyl) porphyrin is 10;
the reaction temperature is 60-200 ℃, the reaction time is 24-60 hours, preferably, the reaction temperature is 140 ℃, and the reaction time is 48 hours.
(4) And dispersing the europium porphyrin black phosphorus compound in a 15mL of DMF solution, adding zinc acetate, heating and refluxing the solution, centrifuging after the reaction is finished, washing with DMF (dimethyl formamide) and acetonitrile, and drying in vacuum to obtain the europium porphyrin phosphorus cluster material.
Wherein the mass ratio of the europium porphyrin black phosphorus compound to the zinc acetate is 10-1; the reaction temperature is 30-150 ℃, the reaction time is 12-60 hours, preferably, the mass ratio is 1.
Further, the preparation process of the material is carried out under the protection of nitrogen.
The novel zinc-europium porphyrin phosphorus cluster material (BP @ Eu-TCPP-Zn) prepared by the invention has stability in aqueous solution, improves the capability of absorbing near infrared light and converting the near infrared light into heat, and has the function of catalyzing NAD (nicotinamide adenine dinucleotide) under sunlight + The reducing property of (2). Compared with the traditional black phosphorus, the porphyrin zinc europium modified black phosphorus has high light conversion capability and can accept light to generate electrons, so that NAD (nicotinamide adenine dinucleotide) + Reduced to NADH, therefore, BP @ Eu-TCPP-Zn is a novel NAD + Light-driven NAD (NAD) with reducing agent BP @ Eu-TCPP-Zn as catalyst + The reduction is different from the traditional NAD + A reducing agent coordinated to the active metal; the modification of hydrophobic porphyrin ensures that BP @ Eu-TCPP-Zn has good stability, can be recycled, and has stability superior to that of the traditional complex NAD + A reducing agent. Therefore, the material of the invention is actually a novel light-driven NAD (nicotinamide adenine dinucleotide) -based material + Reducing agent and its preparation method are provided.
The invention also provides application of the zinc-europium-porphyrin phosphorus cluster material (BP @ Eu-TCPP-Zn), wherein the application is catalytic reduction of NAD + Generating NADH.
The para-NAD + The catalytic reduction method comprises the following steps:
at different light sources(LED blue light, green light, red light and sunlight, preferably sunlight) to irradiate the zinc-europium porphyrin phosphorus cluster material and the NAD + (Add PBS buffer solution, add triethanolamine, every hour using UV spectrophotometer measurements at 340nm UV absorption intensity.
Wherein the zinc europium porphyrin phosphorus cluster material and NAD + The mass ratio of (1): 1, the volume ratio of the PBS buffer solution to the triethanolamine was 4.
The invention has the beneficial effects that:
black scales (BP) has good biocompatibility, near infrared absorption and good photo-thermal performance, and recently, metal modified BP generates Reactive Oxygen Species (ROS) under the action of near infrared light, and kills tumors and bacteria through the ROS, so that the BP is a good photodynamic therapeutic agent. However, the black phosphorus itself is rapidly degraded by exposure to air and water, and the application capability of the black phosphorus is seriously affected. According to the invention, the black phosphorus is modified, so that the stability is improved, and the bacteriostatic ability of the black phosphorus material is improved. The two-dimensional black phosphorus as a nano material consisting of simple substance phosphorus has good near-infrared photo-thermal conversion capability and light absorption capability, and is a good electron transporter. The porphyrin has good hydrophobicity and metal binding capacity, and the stability and the electron transport capacity of the porphyrin-modified black scale can be improved.
The invention reports a preparation method of porphyrin-modified nano material containing metal phosphorus bonds, the prepared zinc-europium-porphyrin-phosphorus cluster material (BP @ Eu-TCPP-Zn) has excellent light absorption effect and near infrared light conversion capability, lone pair electrons of simple substance phosphorus can be coordinated with metal and realize good electron transmission, porphyrin improves the stability of black phosphorus, and the light conversion capability of the enhanced compound can accept light to generate electrons, so that NAD (nicotinamide adenine dinucleotide) can be obtained + Reduction to NADH, BP @ Eu-TCPP-Zn is a novel NAD + Reducing agent, light-driven NAD + The reduction is different from the traditional NAD + The material can be recycled, and the stability of the material is superior to that of the traditional complex NAD + A reducing agent. Thus, the material of the present invention is alsoNovel based on light drive NAD + A reducing agent.
Drawings
FIG. 1 is a schematic structural diagram of a zinc europium porphyrin phosphorus cluster material.
FIG. 2 is a scanning electron microscope and element distribution diagram of the prepared BP @ Eu-TCPP-Zn, wherein a is a scanning diagram of raw material black phosphorus, b is a single scanning diagram of porphyrin zinc europium phosphorus cluster material, C is an EDX element analysis superposition diagram of BP @ Eu-TCPP-Zn, C is an analysis diagram of single element, eu, N, O, P, zn is 1 μm in scale size, and red, yellow, blue, purple, cyan and green fluorescence are respectively shown in the diagram.
FIG. 3 is an infrared spectrum of zinc europium porphyrin phosphorus cluster material BP @ Eu-TCPP-Zn.
FIG. 4 shows photothermal data of zinc europium porphyrin phosphorus cluster materials BP @ Eu-TCPP-Zn and BP in ten minutes, and blank is pure water of the same volume as the reference.
FIG. 5 shows the impedance spectra of BP, BP @ Eu-TCPP and BP @ Eu-TCPP-Zn.
FIG. 6 is a Raman spectrum of BP, BP @ Eu-TCPP.
FIG. 7 is a graph showing the reduction spectrum of BP @ Eu-TCPP-Zn prepared in example 1 on NAD under solar illumination.
FIG. 8 shows the results of the degradation study of BP @ Eu-TCPP-Zn prepared in example 1 and BP as a starting material in an aqueous solution (1 mg/mL).
FIG. 9 is an XPS spectrum of BP @ Eu-TCPP-Zn prepared in Experimental example 1.
Detailed Description
In order to make those skilled in the art better understand the technical solution of the present invention, the following embodiments of the present invention are described in detail, but the following embodiments do not limit the scope of the present invention.
In the examples of the present invention, the experimental methods without specific descriptions of specific conditions were carried out according to the conventional methods and conditions in the art, and the materials used were commercially available in a conventional manner unless otherwise specified.
Reagents and instruments used in the examples of the invention: all solvents used in the reaction were analytically pure, and the reagents used were used without special indication and without any special treatment.
Black scale: nanjing Xiancheng nanomaterial Co., ltd;
n-methylpyrrolidone (NMP), N-Dimethylformamide (DMF): analytically pure, shanghai Pilot plant chemical Co., ltd;
zinc acetate hexahydrate, europium trichloride: analytical grade, shanghai chemical reagents, inc.;
tetra (4-carboxyphenyl) porphyrin (TCPP), n-octylamine: analytically pure, annaiji Co.
Example 1: preparation of zinc-europium porphyrin phosphorus cluster material (marked as BP @ Eu-TCPP-Zn)
In this example, the material preparation process was carried out under nitrogen protection.
(1) Under the protection of nitrogen, 100mg of blocky black phosphorus is ground and dispersed in 90mL of NMP solution, 10mL of n-octylamine is added, and after uniform stirring and mixing, the blocky black phosphorus is ultrasonically stripped for 30 hours by a cell crusher under the condition of 800w of power in an ice bath. And centrifuging at 4000 revolutions after the ultrasonic treatment to obtain an NMP solution containing black scales on the upper layer, centrifuging at 8000 revolutions at a high speed to obtain 90mg of lamellar Black Phosphorus (BP), and storing in dark under nitrogen.
(2) Under the protection of nitrogen, lamellar black phosphorus (32mg, 1mmol) is dispersed in 10mL of DMF solution, europium trichloride (258mg, 1mmol) is dissolved in 10mL of DMF solution, the DMF solution of europium trichloride is slowly dripped into the DMF solution of lamellar black phosphorus, the mixture is stirred for ten minutes at normal temperature, then the mixture is transferred into a reaction kettle to react for 24 hours at 140 ℃,8000 revolutions are carried out after the reaction is finished, the precipitate is centrifugally taken out, DMF is washed for a plurality of times, acetonitrile is used for washing for three times, and vacuum drying is carried out to obtain europium black phosphorus compound (BP @ Eu), 124mg and the compound is stored in a dark place. (in the step, the molar ratio of the lamellar black phosphorus to the europium trichloride is 1
(3) Europium black phosphorus compound (100 mg) is dispersed in DMF (20 mL) solution, tetra (4-carboxyphenyl) porphyrin (100 mg) is ultrasonically dissolved in DMF (10 mL) solution, the two are uniformly mixed and stirred for ten minutes at normal temperature, the mixture is transferred into a reaction kettle to react at 140 ℃ for 48h, the reaction kettle is centrifuged at 8000 turns to collect precipitate, the precipitate is washed by DMF for a plurality of times and acetonitrile for three times, and vacuum drying is carried out to obtain europium black phosphorus porphyrin (BP @ Eu-TCPP), 186mg and the precipitate is stored in dark. (in this step, the mass ratio of the europium black phosphorus compound to tetrakis (4-carboxyphenyl) porphyrin is 1
(4) Taking a porphyrin europium black phosphorus compound (100 mg) to disperse in a DMF (15 mL) solution, adding zinc acetate hexahydrate (100 mg), reacting at 80 ℃ for 12 hours, centrifuging at 8000 turns, collecting precipitate, washing with DMF for a plurality of times, washing with acetonitrile for three times, and drying in vacuum to obtain a porphyrin zinc europium phosphorus cluster material (BP @ Eu-TCPP-Zn), wherein 164mg is stored in a dark place. (in this step, the mass ratio of the europium porphyrin black phosphorus compound to the zinc acetate is 1
Fig. 1 is a schematic structural view of a zinc-europium porphyrin phosphorus cluster material, wherein a is a schematic structural view and b is a perspective structural view.
FIG. 2 is the scanning electron microscope and element distribution diagram of BP @ Eu-TCPP-Zn prepared in this example, in which a is the scanning diagram of black phosphorus as raw material; the figure b is a scanning image of the zinc europium porphyrin phosphorus cluster material, and the surface of unmodified black phosphorus can be found to be smooth, while the surface of the modified black phosphorus is rough; the figure C is an EDX element analysis overlay chart of BP @ Eu-TCPP-Zn, and the figure C is an analysis chart of Eu, N, O, P and Zn which are single elements. It can be seen from the figure that the compound is a lamellar structure with an average width of 1 micron. Meanwhile, the EDX element analysis finds that the constituent elements of the compound comprise C, N, eu, O, P and Zn.
FIG. 3 is an infrared spectrum of BP @ Eu-TCPP-Zn, which is at 1650cm -1 Is the stretching vibration peak of C = O in tetracarboxyl porphyrin, and is 1600-1400cm -1 The presence of porphyrins in the compound is evidenced by the multiple absorption peaks ascribed to the characteristic absorption of porphyrins.
FIG. 4 shows photothermal data of compounds BP @ Eu-TCPP-Zn and BP in ten minutes (concentration of compound is 100. Mu.g/mL, light source is near infrared light 2 w/cm) 2 ) In the figure, blank is the same volume of pure water as a control. The photo-thermal property of the black phosphorus is maintained by comparing the photo-thermal property of the black phosphorus by timing from illumination. Under the same near-infrared illumination of 10 minutes, the photo-thermal effect of the modified compound is improved compared with that of black phosphorus, so that the photo-thermal antibacterial performance of the compound is further improved.
FIG. 5 is an impedance spectrogram of BP, BP @ Eu-TCPP and BP @ Eu-TCPP-Zn, which shows that the impedance of BP @ Eu-TCPP-Zn is reduced, thus indicating that the modification of europium porphyrin improves the transmission capability of electrons (i.e. the impedance is reduced), and experimental data indicates that europium porphyrin increases the conductivity of black phosphorus, and the ability of the material to generate electrons under illumination is improved, thereby improving the reduction catalysis efficiency.
FIG. 6 is a Raman spectrum of BP and BP @ Eu-TCPP, in which it can be seen that BP @ Eu-TCPP is 683cm in comparison with black phosphorus -1 And 737cm -1 May be formed of P-Eu bonds and O-Eu bonds. 2430cm -1 The absorption peak at (a) is derived from the absorption of the porphyrin, which demonstrates the successful modification of black phosphorus by the porphyrin and Eu.
FIG. 9 is an XPS spectrum of BP @ Eu-TCPP-Zn prepared in Experimental example 1. The modified compound can be found to mainly comprise C, N, P, O, zn and Eu elements. Wherein the P spectrum has P-O bonds and P-P bonds. Wherein europium is bonded to phosphorus in a coordinated fashion, predominantly having a valence of 3, and zinc is coordinated to porphyrin, predominantly having a valence of 2.
Example 2: preparation of zinc-europium-porphyrin phosphorus cluster material (BP @ Eu-TCPP-Zn)
In the present example, the material preparation process was performed under nitrogen protection.
(1) Under the protection of nitrogen, 100mg of blocky black phosphorus is ground and dispersed in 40mL of NMP solution, 0.1mL of n-octylamine is added, and after uniform stirring and mixing, the blocky black phosphorus is ultrasonically stripped for 5 hours by a cell crusher under the condition of 800w of power in an ice bath. And centrifuging at 4000 rpm after the ultrasonic treatment is finished, and taking the upper-layer solution to obtain 15mg of a small amount of lamellar Black Phosphorus (BP), and storing in dark nitrogen.
(2) Under the protection of nitrogen, the sample of the lamellar black phosphorus (3.2 mg, 0.1mmol) prepared in step (1) of example 1 was dispersed in 10mL of DMF solution, europium trichloride (25.8mg, 0.1mmol) was dissolved in 10mL of DMF solution, the DMF solution of europium trichloride was slowly added dropwise to the DMF solution of lamellar black phosphorus, after stirring at room temperature for ten minutes, the mixture was transferred to a reaction kettle to react at 80 ℃ for 24 hours, after the reaction was completed, the precipitate was centrifuged at 8000 rpm, washed with DMF several times, washed with acetonitrile three times, and vacuum-dried to obtain 2.1mg of europium black phosphorus compound (BP @ Eu), which was stored away from light. (in the step, the molar ratio of the lamellar black phosphorus to the europium trichloride is 1
(3) And (3) dispersing the europium black phosphorus compound (100 mg) prepared in the step (2) in a DMF (20 mL) solution, ultrasonically dissolving tetra (4-carboxyphenyl) porphyrin (10 mg) in the DMF (5 mL) solution, uniformly mixing the two, stirring for ten minutes at normal temperature, transferring the mixture into a reaction kettle, reacting for 24 hours at 60 ℃, centrifuging at 8000 to collect precipitate, washing with DMF for multiple times, washing with acetonitrile for three times, and drying in vacuum to obtain 5mg of europium black phosphorus porphyrin (BP @ Eu-TCPP), and storing in a dark place. (in this step, the mass ratio of the europium black phosphorus compound to tetrakis (4-carboxyphenyl) porphyrin is 10
(4) And (4) dispersing the porphyrin europium black phosphorus compound (100 mg) in the step (3) in a DMF (15 mL) solution, adding zinc acetate hexahydrate (10 mg), reacting at 30 ℃ for 12 hours, centrifuging at 8000 rpm, collecting precipitate, washing with DMF for multiple times, washing with acetonitrile for three times, and drying in vacuum to obtain 6mg of porphyrin zinc europium phosphorus cluster material (BP @ Eu-TCPP-Zn), and storing in a dark place. ( In the step, the mass ratio of the europium porphyrin black phosphorus compound to the zinc acetate is 10:1 )
Example 3: preparation of zinc-europium-porphyrin phosphorus cluster material (BP @ Eu-TCPP-Zn)
In the present example, the material preparation process was performed under nitrogen protection.
(1) Under the protection of nitrogen, 100mg of blocky black phosphorus is ground and dispersed in 120mL of NMP solution, 20mL of n-octylamine is added, and after uniform stirring and mixing, the blocky black phosphorus is ultrasonically stripped for 60 hours by a cell crusher under the condition of 800w of power in an ice bath. And centrifuging 4000 revolutions after the ultrasonic treatment to obtain an upper layer solution to obtain 40mg of lamellar Black Phosphorus (BP), and storing in a dark nitrogen atmosphere.
(2) Under the protection of nitrogen, a sample of the lamellar black phosphorus (32mg, 1mmol) prepared in the step (1) of example 1 is dispersed in 10mL of DMF solution, europium trichloride (516mg, 20mmol) is dissolved in 10mL of DMF solution, the DMF solution of europium trichloride is slowly dripped into DMF of lamellar black phosphorus, the mixture is stirred for ten minutes at normal temperature and then transferred into a reaction kettle to react for 24 hours at 200 ℃,8000 revolutions after the reaction is finished, precipitate is centrifugally taken out, DMF is used for multiple times of washing, acetonitrile is used for three times, and the europium black phosphorus compound (BP @ Eu) is obtained after vacuum drying, 25.2mg is obtained and is stored in a dark place. (in the step, the molar ratio of the lamellar black phosphorus to the europium trichloride is 1
(3) And (3) dispersing the europium black phosphorus compound (100 mg) prepared in the step (2) in a DMF (20 mL) solution, ultrasonically dissolving tetra (4-carboxyphenyl) porphyrin (200 mg) in the DMF (20 mL) solution, uniformly mixing the two, stirring for ten minutes at normal temperature, transferring the mixture into a reaction kettle, reacting for 60 hours at 200 ℃, centrifuging at 8000 turns, collecting precipitate, washing with DMF for multiple times, washing with acetonitrile for three times, and drying in vacuum to obtain europium black phosphorus porphyrin (BP @ Eu-TCPP), 65mg and storing in a dark place. (in this step, the mass ratio of the europium black phosphorus compound to tetrakis (4-carboxyphenyl) porphyrin is 1
(4) And (3) dispersing the porphyrin europium black phosphorus compound (100 mg) in the step (3) into a DMF (15 mL) solution, adding zinc acetate hexahydrate (200 mg), reacting at 150 ℃ for 10 hours, centrifuging at 8000 turns, collecting precipitate, washing with DMF for multiple times, washing with acetonitrile for three times, and drying in vacuum to obtain the porphyrin europium black phosphorus cluster material (BP @ Eu-TCPP-Zn), wherein the weight of the porphyrin europium black phosphorus cluster material is 60mg and the porphyrin europium black phosphorus cluster material is stored in a dark place. (in this step, the mass ratio of the europium porphyrin black phosphorus compound to the zinc acetate is 1
Example 4:
in the present example, the material preparation process was performed under nitrogen protection.
The europium porphyrin black phosphorus compound (100 mg) in the step (3) in the example 1 is dispersed in DMF (15 mL), zinc acetate hexahydrate (150 mg) is added to react at 100 ℃ for 60 hours, the precipitate is collected by centrifugation at 8000 turns, after being washed by DMF for a plurality of times, acetonitrile is used for washing for three times, and vacuum drying is carried out to obtain zinc europium porphyrin phosphorus cluster (BP @ Eu-TCPP-Zn), 120mg, and the zinc europium porphyrin phosphorus cluster is stored away from light. (in the step, the mass ratio of the europium porphyrin black phosphorus compound to the zinc acetate is 1
Example 5: BP @ Eu-TCPP-Zn vs. NAD + Reduction catalysis experiment of
Respectively preparing aqueous solution of BP @ Eu-TCPP-Zn compound and NAD with concentration of 1mg/mL + Aqueous solution, sodium Phosphate (PBS) buffer solution pH =7.4 was prepared.
300 mul BP @ Eu-TCPP-Zn aqueous solution with concentration of 1mg/mL and NAD are respectively taken + 0.6mL of triethanolamine and 2.34mL of PBS buffer were added to the aqueous solution, and the amount of NADH produced was evaluated by taking the solution every one hour to measure the ultraviolet absorbance at 340nm under the water bath condition at 37 ℃ from the start of the solar irradiation.
FIG. 7 is a graph of BP @ Eu-TCPP-Zn prepared in example 1 vs. NAD under sunlight + The reduction spectrum of (a). The absorption peak at 340nm is the characteristic absorption peak of NADH, and can be seen in the figureBP @ Eu-TCPP-Zn can absorb sunlight to lead NAD to + Reducing to NADH.
Example 6: BP vs. NAD + Reduction catalysis experiment of
Respectively preparing aqueous solution of BP compound with concentration of 1mg/mL and NAD + Aqueous solution, sodium Phosphate (PBS) buffer solution pH =7.4 was prepared.
300. Mu.L of BP and NAD with a concentration of 1mg/mL, respectively + 0.6mL of triethanolamine and 2.34mL of PBS buffer were added to the aqueous solution, and the amount of NADH produced was evaluated by taking the solution every one hour to measure the ultraviolet absorbance at 340nm under the water bath condition at 37 ℃ from the start of the solar irradiation. The experiment shows that no absorption peak appears at 340nm, which indicates that BP can not reduce NAD + 。
Meanwhile, the prepared material BP @ Eu-TCPP-Zn and the raw material BP are tested in the invention for degradation or stability in aqueous solution.
FIG. 8 is a degradation study of BP @ Eu-TCPP-Zn prepared in example 1 and BP as a raw material in an aqueous solution (1 mg/mL). Through testing the three-day degradation condition, the stability of the modified compound BP @ Eu-TCPP-Zn is obviously improved.
Claims (12)
1. The zinc-europium-porphyrin-phosphorus cluster material is characterized by being of a lamellar structure and marked as BP @ Eu-TCPP-Zn, wherein the mass percent of metal europium and zinc in the zinc-europium-porphyrin-phosphorus cluster material are respectively 1.5% and 6.8%, and the zinc-europium-porphyrin-phosphorus cluster material contains europium black phosphorus and tetra (4-carboxyphenyl) zinc porphyrin; the material comprises the following components of C, N, eu, O, P and Zn; raman and XPS spectra show P-Eu and P-P bonds.
2. A method for preparing the material of claim 1, comprising the steps of:
(1) Adding blocky black phosphorus and N-octylamine into an N-methylpyrrolidone (NMP) solution, and carrying out ultrasonic stripping under ice bath to obtain lamellar black phosphorus;
(2) Respectively dispersing lamellar black phosphorus and europium trichloride in a DMF (dimethyl formamide) solution, slowly dropwise adding the DMF solution of europium trichloride into the DMF solution of lamellar black phosphorus, uniformly mixing, centrifuging after the reaction is finished, washing with DMF and acetonitrile, and drying in vacuum to obtain a europium black phosphorus compound;
(3) Respectively dispersing the europium black phosphorus compound and tetra (4-carboxyphenyl) porphyrin in a DMF solution, uniformly mixing the two solutions, reacting, centrifuging after the reaction is finished, washing with DMF and acetonitrile, and drying in vacuum to obtain the europium black phosphorus porphyrin;
(4) And dispersing the europium porphyrin black phosphorus compound in a DMF solution, adding zinc acetate, heating and refluxing the solution, centrifuging after the reaction is finished, washing with DMF and acetonitrile, and drying in vacuum to obtain the europium porphyrin phosphorus cluster material.
3. The method according to claim 2, wherein the ratio of the used amount of the bulk black phosphorus, NMP and n-octylamine in step (1) is as follows: 100mg:40-120mL:0.1-20mL, the ultrasonic power is 800w, and the ultrasonic time is 5-60 hours.
4. The method according to claim 3, wherein the ratio of the black phosphorus, NMP and n-octylamine is as follows: 100mg:90mL of: 10mL, the sonication time was 30 hours.
5. The method according to claim 2, wherein the molar ratio of the lamellar black phosphorus to the europium trichloride in the step (2) is 1-20.
6. The method according to claim 5, wherein the molar ratio of the lamellar black phosphorus to the europium trichloride is 1, the reaction temperature is 140 ℃ and the reaction time is 24 hours.
7. The method of claim 2, wherein the mass ratio of the europium black phosphorus compound to tetrakis (4-carboxyphenyl) porphyrin in step (3) is 10; the reaction temperature is 60-140 ℃, and the reaction time is 24-60 hours.
8. The method of claim 7, wherein the mass ratio of the europium black phosphorus compound to tetrakis (4-carboxyphenyl) porphyrin in step (3) is 1; the reaction temperature is 140 ℃ and the reaction time is 48 hours.
9. The method of claim 2, wherein the mass ratio of the europium porphyrin black phosphorus compound to the zinc acetate in the step (4) is 10-1.
10. The method of claim 9, wherein the mass ratio of the europium porphyrin black phosphorus compound to the zinc acetate in step (4) is 1; the reaction temperature is 80 ℃ and the reaction time is 12 hours.
11. The method of claim 2, wherein the method is performed under a nitrogen blanket.
12. The use of a material according to claim 1 or prepared according to a process according to any one of claims 2 to 11 in the catalytic reduction of NAD in the field of non-disease diagnosis and therapy + Use in the production of NADH.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210288425.1A CN114736209B (en) | 2022-03-23 | 2022-03-23 | Zinc-europium-porphyrin phosphorus cluster material and preparation method and application thereof |
GB2314001.5A GB2619448B (en) | 2022-03-23 | 2022-04-17 | Zinc-europium-phosphorus porphyrin cluster material and preparation method and use thereof |
PCT/CN2023/088696 WO2023179799A1 (en) | 2022-03-23 | 2023-04-17 | Porphyrin zinc europium phosphorus cluster material, preparation method therefor and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210288425.1A CN114736209B (en) | 2022-03-23 | 2022-03-23 | Zinc-europium-porphyrin phosphorus cluster material and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114736209A CN114736209A (en) | 2022-07-12 |
CN114736209B true CN114736209B (en) | 2023-04-11 |
Family
ID=82277486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210288425.1A Active CN114736209B (en) | 2022-03-23 | 2022-03-23 | Zinc-europium-porphyrin phosphorus cluster material and preparation method and application thereof |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN114736209B (en) |
GB (1) | GB2619448B (en) |
WO (1) | WO2023179799A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114736209B (en) * | 2022-03-23 | 2023-04-11 | 江苏大学 | Zinc-europium-porphyrin phosphorus cluster material and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017075057A1 (en) * | 2015-10-26 | 2017-05-04 | Immunolight, Llc | Methods for radiotherapy to trigger light activation drugs |
WO2019043701A1 (en) * | 2017-08-28 | 2019-03-07 | Bar-Ilan University | Core-shell particles comprising metal oxide and lanthanide element |
CN113735886A (en) * | 2020-05-13 | 2021-12-03 | 北京大学 | PDT compounds, methods of preparation and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100437549B1 (en) * | 2001-10-09 | 2004-06-30 | 김환규 | Lanthanide-chelated porphyrins with porphyrin-linked dendrons having light-harvesting effect and their synthetic methods |
KR100575350B1 (en) * | 2003-12-31 | 2006-05-03 | 김환규 | Lanthanide-chelated porphyrins with porphyrin-linked dendrons having light-harvesting effect |
WO2015164485A1 (en) * | 2014-04-22 | 2015-10-29 | Immunolight, Llc. | Tumor imaging using photon-emitting phosphorus having therapeutic properties |
CN110316707A (en) * | 2019-08-07 | 2019-10-11 | 深圳市中科墨磷科技有限公司 | A method of quickly preparing ion coordination modification black phosphorus nanometer sheet |
CN113061260B (en) * | 2021-03-19 | 2022-04-29 | 暨南大学 | Rare earth metal porphyrin framework material and preparation method and application method thereof |
CN113234235B (en) * | 2021-06-22 | 2022-04-01 | 浙江理工大学 | Preparation method of meso-tetra (4-carboxyphenyl) zinc porphyrin-MOF material for detecting lead |
CN114736209B (en) * | 2022-03-23 | 2023-04-11 | 江苏大学 | Zinc-europium-porphyrin phosphorus cluster material and preparation method and application thereof |
-
2022
- 2022-03-23 CN CN202210288425.1A patent/CN114736209B/en active Active
- 2022-04-17 GB GB2314001.5A patent/GB2619448B/en active Active
-
2023
- 2023-04-17 WO PCT/CN2023/088696 patent/WO2023179799A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017075057A1 (en) * | 2015-10-26 | 2017-05-04 | Immunolight, Llc | Methods for radiotherapy to trigger light activation drugs |
WO2019043701A1 (en) * | 2017-08-28 | 2019-03-07 | Bar-Ilan University | Core-shell particles comprising metal oxide and lanthanide element |
CN113735886A (en) * | 2020-05-13 | 2021-12-03 | 北京大学 | PDT compounds, methods of preparation and uses thereof |
Non-Patent Citations (1)
Title |
---|
Song, Bo.A Europium(III) Complex as an Efficient Singlet Oxygen Luminescence Probe.Journal of the American Chemical Society.2006,第128卷(第128期),13442-13450. * |
Also Published As
Publication number | Publication date |
---|---|
GB202314001D0 (en) | 2023-10-25 |
GB2619448A (en) | 2023-12-06 |
CN114736209A (en) | 2022-07-12 |
WO2023179799A1 (en) | 2023-09-28 |
GB2619448B (en) | 2024-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Song et al. | Zeolitic imidazolate metal organic framework-8 as an efficient pH-controlled delivery vehicle for zinc phthalocyanine in photodynamic therapy | |
CN112245579B (en) | Photodynamic therapeutic agent for relieving tumor hypoxia and preparation method and application thereof | |
CN110051837B (en) | CuO/ZnO/Au nano-particles and preparation method and application thereof | |
CN114736209B (en) | Zinc-europium-porphyrin phosphorus cluster material and preparation method and application thereof | |
CN106000474B (en) | A kind of porphyrin/titanium dioxide uniformly organizes the preparation method and applications of nanosphere altogether | |
CN113274505B (en) | CoMn-Fe-Talc-based nanocomposite and preparation method and application thereof | |
CN108904805B (en) | Preparation method and application of glutathione-responsive Berlin green nanoparticles | |
Yang et al. | Bactericidal functionalization of wrinkle-free fabrics via covalently bonding TiO 2@ Ag nanoconjugates | |
CN113418901A (en) | Boric acid-based fluorescent nanoprobe (R-CDs/B) for detecting glucose concentration2O3) | |
CN110179979A (en) | A kind of composite material and preparation method and application of the copper-based high efficiency anti-tumor of Novel vulcanization | |
CN103724356A (en) | Fullereneporphyrin derivate photosensitizer as well as preparation method and application thereof | |
Zhang et al. | The photothermal synergy effect of pure Ti 3 C 2 T x in antibacterial reaction and its mechanism | |
Xu et al. | Defective transition metal hydroxide-based nanoagents with hypoxia relief for photothermal-enhanced photodynamic therapy | |
Xia et al. | Copper nanocrystalline-doped folic acid-based super carbon dots for an enhanced antitumor effect in response to tumor microenvironment stimuli | |
CN114848813A (en) | Self-supplying H 2 O 2 /O 2 Metal organic framework coated nano-particles consuming GSH (glutathione) and preparation method and application thereof | |
Shao et al. | Mn-doped single atom nanozyme composited Au for enhancing enzymatic and photothermal therapy | |
CN109081319B (en) | Blue-green fluorescent phosphorus oxide quantum dot material, and preparation method and application thereof | |
Huang et al. | Synthesis and properties of Multi-Stimuli responsive Water-Soluble copolymers with high porphyrin content | |
CN111420055A (en) | Magnetic target self-oxygen-supply nano particle and preparation method and application thereof | |
CN106035351A (en) | Preparation method of photosensitizer-supported polymeric micelle and application of micelle in killing of planktobacteria and bacterial biofilms | |
CN114832861B (en) | Preparation method and application of copper carboxyl phenyl porphyrin sensitized caged titanium dioxide | |
CN115606606A (en) | Novel metal polyphenol network loaded metal oxide antibacterial nanoparticles, preparation method and application | |
CN115385861A (en) | Fluorescent probe and preparation method and application thereof | |
CN109810702B (en) | Nano fluorescent probe with good biocompatibility and preparation method thereof | |
CN108421041B (en) | Photodynamic therapy compound and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |